Effect of cis-platinum(II) amine phosphonate complexes on in vitro platelets reactivity

Acta Toxicologica

Volumn 13, Issue 2, 2005, Pages 113-121

  Kostka, Barbara ^a   Sikora, Joanna ^a   Aranowska, Katarzyna ^a   Para, Jadwiga ^a   Ochocki, Justyn ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Adhesion; Aggregation; New platinum derivatives; Platelets morphological parameters

Indexed keywords

ADENOSINE DIPHOSPHATE; CIS PLATINUM(II) AMINE PHOSPHONATE; CISPLATIN; CISPLATIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; DRUG EFFECT; DRUG SYNTHESIS; HUMAN; MORPHOLOGY; NONHUMAN; SWINE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

SUS SCROFA;

EID: 33744970292     PISSN: 17316383     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Içli F, Karaoǧuz H, Dinçol D, Demirkazik A, Günel N, Karaoguz R, et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 1993;72:587-93.
2. Kuenen B, Rosen L, Smit E, Parson M, Levi M, Ruijter R, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumours. J Clin Oncol 2002;20:1657-67.
3. Weijl N, Rutten M, Zwinderman A, Keizer H, Nooy M, Rosendaal F, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 2000;18:2169-78.
4. Nomura S, Yasunaga K. Influence of platelet-derived microparticles on coagulation in a lung cancer patient receiving chemotherapy. Chest 1993;103:979-80.
5. Kuenen B, Levi M, Meijers J, Hinsbergh V van, Berkhof J, Kakkar A, et al. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol 2003;21:2192-98.
6. Panella T, Peters W, White J, Hannun Y, Greenberg C. Platelets acquire a secretion defect after high-dose chemotherapy. Cancer 1990;65:1711-16.
7. Pignatelli P, Properzi E, Piseni M, Clerico A, Schiavetti A, Lenti L, et al. Effects on platelet function of combination etoposide and carboplatin chemotherapy in pediatric oncology patients. Platelets 1998;9:309-14.
8. Dalla Via L, Di Noto V, Vidali M, Scomazzon F, Ni D, Deana R. Action of antitumoral platinum complexes on in vitro platelet functions. Chem Biol Interact 1998;110:203-20.
9. Olas B, Wachowicz B. Inhibitory effects of cisplatin and its conjugate with glutathione on blood platelet activity. Platelets 1998;9:69-72.
10. Olas B, Wachowicz B, Buczyński A. Adhesion of blood platelets to collagen and fibrinogen after treatment with cisplatin and its complex with glutathione. Cytobios 2000;102:75-84.
11. Togna G, Togna A, Franconi M, Caprino L. Cisplatin triggers platelet activation. Throm Res 2000;99:503-09.
12. Yasuhico M, Tetuya M, Yutaka K, Hirofumi K, Kazuyuki Y, Hideo K, et al. Cisplatin-dependent P-selectin expression on platelet surface. In: Davie EW, Kakishita E, editors. Blood Coagulation, Fibrinolysis, and Platelets. Tokyo: Springer-Verlag; 1996. pp. 139-42.
13. Yen T, Walsh J, Pejler G, Berndt M, Geczy C. Cisplatin-induced platelet activation requires mononuclear cells: role of GMP-140 and modulation of procoagulant activity. Brit J Haematol 1993;83:259-69.
14. Kubisz P, Seghier F, Klener P, Holan J. Influence of cis-platinum on some platelet functions in vitro. Neoplasma 1983;30:391-4.
15. Blockmans D, Deckmyn H, Vermylen J. Platelet activation. Blood Rev 1995;9:143-56.
16. Lippert B. Cisplatin: Chemistry and biochemistry of a leading anticancer drug. Zurich: Verlag, Helv Chim Acta and Wiley-VCH Weinheim; 1999. pp. 1-563.
17. Bloemink M, Diederen J, Dorenbos J, Heetebrij R, Keppler B, Reedijk J. Calcium ions do accelerate the DNA binding of new antitumour-active platinum aminophosphonate complexes. Eur J Inorg Chem 1999;10:1655-7.
18. Jakupec M, Galanski M, Keppler B. Tumour-inhibiting platinum complexes -state of the art and future perspectives. Rev Physiol Biochem Pharmacol 2003;146:1-54.
19. Kostka B, Ochocki J. A comparison of the effects of cisplatin and cis-platinum(II) phosphonate complex on ADP-induced platelet aggregation in vitro. Pharmazie 1996;51:990-2.
20. Ochocki J. Polish Patent 171 757; 1997.
21. 2O. Acta Crystallogr 2003;350-2.
22. Ochocki J, Graczyk J, Reedijk J. Synthesis and antitumor activity of novel Pt(II) diethyl pyridylmethylphosphonate complexes against Sarcoma-180. J Inorg Biochem 1995; 59:240.
23. 2O. Die Pharmazie 005 [in press].
24. Ziȩba R, Malinowska K, Wiewiórowski M, Graczyk J. New tumor-inhibiting cisplatin analogues. Acta Pol Pharm 2000;57:136-8.
25. Brzezińska-Błaszczyk E, Mińcikiewicz M, Ochocki J. Effect of cisplatin and cis-platinum(II) phosphonate complex on murine mast cells. Eur J Pharmacol 1996; 298:155-8.
26. Sikora J, Krajewska U, Gietka M, Kostka B. The application of pig blood in the in vitro measurement of platelet adhesion. Pharmazie 2001;56:187-8.
27. Bellavite P, Andrioli G, Guzzo P, Arigliano P, Chirumbolo S, Manzato F, et al. A colorimetric method for the measurement of platelet adhesion in plates. Anal Biochem 1994;216:444-50.
28. Born G. Aggregation of blood platelets by ADP and its reversal. Nature 1962;195:927-35.
29. Kostka B, Paja̧k W. The aggregometer equipment for recording of transmittance (T) with the possibility of scale extension [in Polish]. Diagn Lab 1985;21:43-7.
30. Kostka B. Potentiation of ADP-induced platelet aggregation by mercury compounds. Thromb Res 1990;57:795-801.
31. DeConti R, Toftness B, Lange R, Creasey W. Clinical and pharmacological studies with cis-diamminedichloroplatinum(II). Cancer Res 1973;33:1310-5.
32. Boisdron-Celle M, Lebouil A, Allain P, Gamelin E. Pharmacokinetic properties of platinium derivatives. Bull Cancer 2001;88S:14-9.
33. Gietema J, Meinardi M, Messerschmidt J, Gelevert T, Alt F, Uges D, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000;355:1075-6.
34. Meinardi M, Gietema J, Graaf W van der, Veldhuisen D van, Runne M, Sluiter W, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18:1725-32.
35. Pulcinelli F, Manzari G, Bartoli M, Faggioni A, La Mancusa R, Pavan A, et al. Mechanisms of the platelet proaggregating activity of human carcinoma A 431 cells. Platelets 1995; 6:213-20.
36. Pletscher A. Platelets as models: Use and limitations. Experientia 1988;44:152-5.
37. Softeland E, Hervig T, Framstad T, Holmsen H. Simple method for labelling of porcine platelets with indium-111 oxine. Lab Anim Sci 1995;45:195-8.
38. Ravanat C, Freund M, Dol Y, Cadroy Y, Roussi J, Incardona F, et al. Cross-reactivity of human molecular markers for detection of prothrombotic states in various animal species. Blood Coag Fibrinol 1995;6:446-55.
39. Bick R. Platelet function defects: A clinical review. Semin Thromb Hemost 1992;18:167-85.
40. Luckey T, Venugopal B, Hutcheson D. Heavy metal toxicity, safety and hormology. In: Coulston F, Korte F, editors. Environmental quality and safety. Suppl. Vol 1. Georg Thieme Publishers, Stuttgart; Academic Press New York 1975. pp. 81-104.